Literature DB >> 15118395

Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.

U Schiemann1, Y Müller-Koch, M Gross, J Daum, P Lohse, G Baretton, M Muders, T Mussack, R Kopp, E Holinski-Feder.   

Abstract

BACKGROUND: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disorder predisposing to predominantly colorectal cancer (CRC) and endometrial cancer frequently due to germline mutations in DNA mismatch repair (MMR) genes, mainly MLH1, MSH2 and also MSH6 in families seen to demonstrate an excess of endometrial cancer. As a consequence, tumors in HNPCC reveal alterations in the length of simple repetitive genomic sequences like poly-A, poly-T, CA or GT repeats (microsatellites) in at least 90% of the cases. AIM OF THE STUDY: The study cohort consisted of 25 HNPCC index patients (19 Amsterdam positive, 6 Bethesda positive) who revealed a microsatellite stable (MSS)--or low instable (MSI-L)--tumor phenotype with negative mutation analysis for the MMR genes MLH1 and MSH2. An extended marker panel (BAT40, D10S197, D13S153, D18S58, MYCL1) was analyzed for the tumors of these patients with regard to three aspects. First, to reconfirm the MSI-L phenotype found by the standard panel; second, to find minor MSIs which might point towards an MSH6 mutation, and third, to reconfirm the MSS status of hereditary tumors. The reconfirmation of the MSS status of tumors not caused by mutations in the MMR genes should allow one to define another entity of hereditary CRC. Their clinical features were compared with those of 150 patients with sporadic CRCs.
RESULTS: In this way, 17 MSS and 8 MSI-L tumors were reclassified as 5 MSS, 18 MSI-L and even 2 MSI-H (high instability) tumors, the last being seen to demonstrate at least 4 instable markers out of 10. Among all family members, 87 malignancies were documented. The mean age of onset for CRCs was the lowest in the MSI-H-phenotyped patients with 40.5 +/- 4.9 years (vs. 47.0 +/- 14.6 and 49.8 +/- 11.9 years in MSI-L- and MSS-phenotyped patients, respectively). The percentage of CRC was the highest in families with MSS-phenotyped tumors (88%), followed by MSI-L-phenotyped (78%) and then by MSI-H-phenotyped (67%) tumors. MSS tumors were preferentially localized in the distal colon supposing a similar biologic behavior like sporadic CRC. MSH6 mutation analysis for the MSI-L and MSI-H patients revealed one truncating mutation for a patient initially with an MSS tumor, which was reclassified as MSI-L by analyzing the extended marker panel.
CONCLUSION: Extended microsatellite analysis serves to evaluate the sensitivity of the reference panel for HNPCC detection and permits phenotype confirmation or upgrading. Additionally, it confirms the MSS status of hereditary CRCs not caused by the common mutations in the MMR genes and provides hints to another entity of hereditary CRC. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118395     DOI: 10.1159/000078223

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  12 in total

Review 1.  Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome.

Authors:  Noralane M Lindor
Journal:  Surg Oncol Clin N Am       Date:  2009-10       Impact factor: 3.495

2.  Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer.

Authors:  Y Mueller-Koch; H Vogelsang; R Kopp; P Lohse; G Keller; D Aust; M Muders; M Gross; J Daum; U Schiemann; M Grabowski; M Scholz; B Kerker; I Becker; G Henke; E Holinski-Feder
Journal:  Gut       Date:  2005-06-14       Impact factor: 23.059

3.  Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases.

Authors:  Colloca Giuseppe; Venturino Antonella
Journal:  Int J Colorectal Dis       Date:  2017-05-10       Impact factor: 2.571

4.  Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.

Authors:  Monika Morak; Sarah Käsbauer; Martina Kerscher; Andreas Laner; Anke M Nissen; Anna Benet-Pagès; Hans K Schackert; Gisela Keller; Trisari Massdorf; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  Molecular analysis: microsatellity instability and loss of heterozygosity of tumor suppressor gene in hereditary non-polyposis colorectal cancers (HNPCC).

Authors:  Vesna Hadziavdić; Nada Pavlović-Calić; Izet Eminović
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

6.  Microsatellite instability and loss of heterozygosity of tumor suppressor genes in Bosnian patients with sporadic colorectal cancer.

Authors:  Vesna Hadziavdić; Nada Pavlović-Calić; Izet Eminović
Journal:  Bosn J Basic Med Sci       Date:  2008-11       Impact factor: 3.363

7.  Primary mucinous adenocarcinoma of the vermiform appendix with high grade microsatellite instability.

Authors:  Moritz Komm; Michaela Kronawitter-Fesl; Marcus Kremer; Ludwig Lutz; Elke Holinski-Feder; Reinhard Kopp
Journal:  J Cancer       Date:  2011-05-23       Impact factor: 4.207

8.  Discovery of EST-SSRs in lung cancer: tagged ESTs with SSRs lead to differential amino acid and protein expression patterns in cancerous tissues.

Authors:  Mohammad Reza Bakhtiarizadeh; Mansour Ebrahimi; Esmaeil Ebrahimie
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

9.  Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform.

Authors:  Isabel Förster; Michael Brockmann; Oliver Schildgen; Verena Schildgen
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

10.  Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer.

Authors:  S Shiovitz; W K Copeland; M N Passarelli; A N Burnett-Hartman; W M Grady; J D Potter; S Gallinger; D D Buchanan; C Rosty; A K Win; M Jenkins; S N Thibodeau; R Haile; J A Baron; L L Marchand; P A Newcomb; N M Lindor
Journal:  Br J Cancer       Date:  2014-06-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.